Mushrooms and Diabetic Complications
6 distinct mechanisms identified
A 2022 review mapped six pathways through which Cordyceps sinensis extracts act on diabetic kidney disease: anti-hyperglycemic, anti-inflammatory, immunomodulatory, anti-oxidant, anti-fibrotic, and apoptosis regulation.
Liu et al., Frontiers in Pharmacology, 2022
Anti-fibrotic
EMT inhibition via p38/ERK
Autophagy rescue
dose-dependent in DN rats
Podocyte protection
nephrin and podocin restored
Liu et al., Frontiers in Pharmacology, 2022
View as image ↗Diabetic kidney disease (DKD) is the leading cause of end-stage renal failure worldwide, and current treatments focus on managing blood sugar, blood pressure, and proteinuria without effectively halting kidney decline. Cordyceps sinensis, a fungus used in traditional Chinese medicine for centuries, has drawn research attention for its effects on multiple renal damage pathways in diabetic models. A 2022 review in Frontiers in Pharmacology mapped six distinct biological activities through which Cordyceps extracts act on DKD: anti-hyperglycemic, anti-inflammatory, immunomodulatory, anti-oxidant, anti-fibrotic, and apoptosis-regulating.[1]
The mechanistic evidence base is entirely preclinical. Rat and mouse models dominate, with cell culture studies providing molecular detail. Human data exists, but in a very particular form: three Cordyceps preparations — Bailing capsule, Zhiling capsule, and Jinshuibao capsule — are approved for clinical treatment of DKD in China, and they have been tested almost exclusively as add-on therapy to conventional drugs rather than on their own.[1] That produces an unusual split, which this article treats as its central problem: the preclinical work is molecularly precise but confined to rodents, while the clinical work involves thousands of patients but is methodologically weak enough that its own reviewers discount it. This article synthesizes what the animal and cell data show, where the mechanisms converge, what the human trials actually found, and what the evidence does not yet support. For related coverage of cordyceps and glucose metabolism, see Cordyceps and blood sugar: hypoglycemic research. For kidney function biomarkers, see Cordyceps and creatinine levels: what the studies show.
Key Takeaways
- Liu et al. (2022) identified six biological activities of Cordyceps sinensis extracts relevant to diabetic kidney disease: anti-hyperglycemic, anti-inflammatory, immunomodulatory, anti-oxidant, anti-fibrotic, and regulation of apoptosis
- Dong et al. (2019) demonstrated that a nucleoside-rich Cordyceps extract inhibited epithelial-mesenchymal transition and reduced renal fibrosis in diabetic mice through p38/ERK signaling suppression
- Cao et al. (2019) showed cordycepin induced autophagy in a dose-dependent manner in diabetic nephropathy rats, reducing fibrosis markers alpha-SMA, t-TG, and TIMP-1; adding the autophagy inhibitor 3-MA abolished these benefits
- Hao et al. (2014) found that Cordyceps sinensis treatment in diabetic rats reduced 24-hour urinary protein and kidney weight-to-body weight ratio (P<0.01 vs. diabetic controls) while restoring podocyte markers nephrin and podocin
- Zheng et al. (2023) identified a specific molecular axis: cordycepin from Cordyceps militaris ameliorated diabetic nephropathy in mice through the miR-193b-5p/MCL-1 pathway, reducing oxidative stress and inflammation
- The mechanistic studies are all preclinical (animal and cell models), but human trials do exist: Tan et al. (2022) identified four meta-analyses of Bailing and Jinshuibao capsules in diabetic nephropathy — the largest pooling 60 studies and 4,288 participants — all finding Cordyceps plus an ACE inhibitor or ARB superior to the drug alone
- Those same reviewers discount their own pooled result: participants were uniformly Chinese, most trials did not report detailed methodology, efficacy assessments were not standardized, and low design quality plus heterogeneity "reduced the credibility of the meta-analysis"
- No trial has tested whether cordyceps slows progression to end-stage renal failure rather than improving biomarkers, and none has compared it head-to-head against standard-of-care kidney-protective drugs
What Happens to the Kidneys in Diabetes
Sustained high blood glucose damages the glomeruli (the filtering units) and the tubulointerstitial compartment (the tubules and surrounding tissue) through several converging processes. Excess glucose generates advanced glycation end products (AGEs), which activate inflammatory signaling. Oxidative stress accumulates as mitochondria overproduce reactive oxygen species (ROS). The mesangial matrix expands, the glomerular basement membrane thickens, and podocytes (specialized cells that maintain the filtration barrier) are injured and lost. For a broader look at AGE accumulation, see Mushroom antioxidants and advanced glycation end products (AGEs) in diabetes.
As damage progresses, tubular epithelial cells undergo epithelial-mesenchymal transition (EMT), converting from functional epithelial cells into fibroblast-like cells that deposit extracellular matrix. This fibrosis is what ultimately destroys the kidney's architecture. The progression from early proteinuria to end-stage renal failure can span decades, but once established, fibrosis is largely irreversible with current therapies.
Cordyceps research targets several of these steps: podocyte protection, EMT inhibition, fibrosis reduction, oxidative stress scavenging, and inflammatory cytokine suppression.
One Cascade, Six Intervention Points
Where Each Cordyceps Study Enters the Damage Chain
Diabetic kidney disease is a sequence, not an event. The six preclinical studies in this article are usually listed as separate findings, but each one intervenes at a different link in the same chain — which is what makes the mechanistic convergence real, and also why no single target can be credited with the effect.
Sustained hyperglycemia
Excess glucose generates advanced glycation end products and drives mitochondrial overproduction of reactive oxygen species.
Cordyceps sinensis[1]Anti-hyperglycemic activity is one of the six biological activities catalogued by the 2022 review; blood sugar also fell dose-dependently in the cordycepin rat study [4]
Oxidative stress
Antioxidant capacity is overwhelmed; lipid peroxidation rises and MAPK stress signalling is activated.
Cordyceps sinensis[7]MDA down, T-AOC and SOD up; JNK down and ERK up; comparable to probucol in this model
Tubular cell apoptosis
Proximal tubular cells die under glucose stress — the compartment whose dysfunction correlates most closely with DKD progression.
Fermented Cordyceps[2]Bax, Caspase-3, VEGFA, P-AKT and P-ERK down; PTEN up; proliferation restored in HK-2 cells
Cordycepin[5]Reversed the high-glucose rise in miR-193b-5p and fall in MCL-1; MCL-1 confirmed as a direct target
Podocyte injury and loss
Slit-diaphragm proteins are lost and the filtration barrier leaks. Podocytes do not regenerate.
Cordyceps sinensis[6]Nephrin and podocin expression restored; KW/BW and 24-h urinary protein reduced (P<0.01)
Epithelial-mesenchymal transition
Tubular epithelial cells convert to fibroblast-like cells and begin depositing extracellular matrix.
CS-N nucleoside extract[3]EMT and ECM accumulation inhibited through suppression of p38 and ERK signalling
Established renal fibrosis
Matrix replaces functional tissue. Once established, fibrosis is largely irreversible with current therapies.
Cordycepin[4]alpha-SMA, t-TG and TIMP-1 suppressed via autophagy induction; 3-MA blockade abolished the effect
End-stage renal failure
The outcome that defines the disease, and the only one patients ultimately care about.
No intervention node. No cordyceps study — preclinical or clinical — has measured progression to this endpoint.
Reading the diagram
Green boxes mark where a study reported an effect; the chain itself is the disease. The coverage looks comprehensive, and in a mechanistic sense it is — but note that steps 01 through 06 are all intermediate biology measured in rodents and cell lines, while step 07 is unmeasured. A therapy can move every marker on this chain and still not change the ending, which is exactly the question the human trials were never designed to answer.
Source: Liu 2022; Zhang 2023; Dong 2019; Cao 2019; Zheng 2023; Hao 2014; Zhao 2018 (see references)
Protecting Tubular Cells from High-Glucose Damage
Zhang et al. (2023) examined fermented Cordyceps sinensis in HK-2 cells (a human kidney proximal tubular cell line) exposed to 30 mM glucose. Using network pharmacology and molecular docking, the team identified nine key therapeutic targets, including RELA, PTEN, VEGFA, Caspase-3, and AKT1. Experimental verification showed that fermented Cordyceps reduced high-glucose-induced cell death and promoted proliferation.[2]
Specifically, the extract downregulated Bax and Caspase-3 (pro-apoptotic markers), reduced phosphorylated AKT and ERK signaling, and upregulated PTEN. The study positions the AKT and ERK pathways as critical mechanisms for fermented Cordyceps in DKD. The limitation is that HK-2 cells in a dish respond to sustained 30 mM glucose differently than tubular cells in a living kidney with vascular supply, immune cells, and hemodynamic stress.
Inhibiting Epithelial-Mesenchymal Transition and Renal Fibrosis
Dong et al. (2019) isolated a nucleoside/nucleobase-rich extract from Cordyceps sinensis (designated CS-N) using microporous resin and glucan column purification, then characterized its composition via HPLC-DAD and LC-MS. In streptozotocin-induced diabetic mice, CS-N attenuated abnormal renal function parameters, ameliorated histopathological changes, and inhibited both EMT and extracellular matrix (ECM) accumulation.[3]
The mechanism mapped to p38 and ERK signaling pathways. CS-N suppressed the activation of both kinases, which are upstream drivers of EMT in renal tubular cells. The parallel in vitro experiments in HK-2 cells exposed to high glucose confirmed these findings. This is one of the cleaner mechanistic demonstrations in the cordyceps-kidney literature because the extract was chemically characterized (nucleosides and nucleobases identified) rather than being an undefined whole-fungus preparation.
Cordycepin and Autophagy Rescue
Cordycepin (3'-deoxyadenosine), the signature bioactive compound of Cordyceps militaris, has been tested directly in diabetic nephropathy models. Cao et al. (2019) divided diabetic rats into low-dose (10 mg/kg), medium-dose (100 mg/kg), and high-dose (500 mg/kg) cordycepin groups and measured metabolic, inflammatory, and histological outcomes after treatment.[4]
All cordycepin doses reduced blood cholesterol, triglycerides, creatinine, and urinary protein versus diabetic controls, with dose-dependent improvements. Inflammatory cytokines IL-1-beta, IL-6, and IL-18 declined. Fibrosis markers alpha-SMA, t-TG, and TIMP-1 were suppressed. The critical finding was on autophagy: cordycepin rescued autophagy markers Beclin1 and LC3-I/II while reducing p62 (an autophagy substrate that accumulates when autophagy is impaired).
The causal test came in the study's in vitro arm. When the researchers added 3-methyladenine (3-MA), a specific autophagy inhibitor, the protective effect of cordycepin on renal fibrosis was abolished — apoptosis and fibrosis returned. That is the difference between a correlation and a mechanism: autophagy induction is required for cordycepin's anti-fibrotic effect, not merely something that happens alongside it. The authors state this was the first demonstration of autophagy-dependent cordycepin protection in diabetic nephropathy.
Cao et al. (2019) · International Urology and Nephrology
- Population
- Diabetic nephropathy rat model, randomized to normal control, diabetic control, and three cordycepin doses (10, 100, 500 mg/kg), plus parallel in vitro experiments
- Intervention
- Cordycepin at 10, 100 or 500 mg/kg
- Comparator
- Untreated diabetic controls; and, in vitro, cordycepin plus the autophagy inhibitor 3-methyladenine
- Finding
- Cholesterol, blood sugar, triglyceride, creatinine and urine protein all improved versus diabetic controls in a dose-dependent manner, with reduced tissue damage on histology. Cordycepin suppressed apoptosis and renal fibrosis and rescued autophagy (Beclin1, LC3-I/II up; p62 down). Adding 3-MA in vitro abolished the anti-fibrotic protection.
positive Strong and unusually well-controlled for this literature because of the 3-MA blockade, which establishes autophagy as necessary rather than incidental. It remains a rodent and cell study — the doses span a 50-fold range and none of them have been tested in humans for this indication.
Cao et al., International Urology and Nephrology, 2019 [4]
The miR-193b-5p/MCL-1 Axis
Zheng et al. (2023) added molecular specificity to the cordycepin story. In diabetic nephropathy mice and in HK-2 cells treated with high glucose, the team found that miR-193b-5p levels were elevated while MCL-1 (myeloid cell leukemia 1, an anti-apoptotic protein) was downregulated. Cordycepin reversed both changes.[5]
MCL-1 was confirmed as a direct target of miR-193b-5p by luciferase reporter assay. The functional consequence: cordycepin attenuated high-glucose-induced cell damage, inflammation, and abnormal energy metabolism in HK-2 cells through this axis. In the mouse model, DN-related biochemical markers improved and renal histopathology showed less damage. The identification of a specific microRNA target distinguishes this work from the broader pathway-level findings of earlier studies. For the broader diabetic neuropathy picture, see Mushrooms and diabetic complications: neuropathy, retinopathy, and nephropathy research.
Podocyte Protection
Podocytes are terminally differentiated cells on the outer surface of glomerular capillaries. Once lost, they do not regenerate. Podocyte loss directly correlates with proteinuria severity and disease progression in diabetic nephropathy.
Hao et al. (2014) tested Cordyceps sinensis alone, Tripterygium wilfordii polyglycosidium (TWP) alone, and the combination in diabetic rats over 12 weeks. Compared to diabetic controls, the Cordyceps group showed lower kidney weight-to-body weight ratio (P<0.01) and 24-hour urinary protein (P<0.01). Transmission electron microscopy revealed structural improvements in podocyte foot processes. Immunofluorescence showed restored expression of nephrin and podocin, two slit diaphragm proteins essential for maintaining the glomerular filtration barrier.[6]
The combination of CS and TWP produced larger improvements than either agent alone, and the authors concluded that combining the two increased the protective effect. Nephrin and podocin restoration is a meaningful endpoint because these proteins directly maintain the physical barrier that prevents protein leakage into urine.
Hao et al. (2014) · Experimental and Therapeutic Medicine
- Population
- Diabetic nephropathy rat model over 12 weeks, randomized into normal control, DN control, Cordyceps sinensis, Tripterygium wilfordii polyglycosidium, and combination groups
- Intervention
- Cordyceps sinensis alone, or combined with Tripterygium wilfordii polyglycosidium
- Comparator
- Untreated diabetic nephropathy rats
- Finding
- Kidney weight/body weight ratio and 24-hour urinary protein were lower in all three treatment groups than in diabetic controls (P<0.01). Transmission electron microscopy showed pathomorphological improvement in glomeruli, tubules and podocytes, and immunofluorescence showed higher nephrin and podocin expression in renal tissue. The combination outperformed either agent alone.
positive A structural rather than merely biochemical endpoint, which makes it more informative than proteinuria alone. But it is a 12-week rodent study, and the strongest arm pairs Cordyceps with a known immunosuppressant, so the independent contribution of Cordyceps is not cleanly isolated.
Hao et al., Experimental and Therapeutic Medicine, 2014 [6]
For related research on diabetic wound healing with other mushroom species, see Diabetic wound healing and medicinal mushrooms: preclinical evidence.
Oxidative Stress and Contrast-Induced Kidney Injury
Zhao et al. (2018) examined a clinically relevant scenario: contrast-induced nephropathy (CIN) in diabetic rats. Diabetic patients are at elevated CIN risk when undergoing imaging procedures requiring iodinated contrast dye. The study compared Cordyceps sinensis pretreatment against probucol (an established antioxidant drug) in diabetic rats receiving iodixanol contrast agent.[7]
Both CS and probucol groups showed lower serum creatinine, blood urea nitrogen, urinary KIM-1, and NGAL (renal injury biomarkers) compared to untreated diabetic controls (P<0.05), with no measurable difference between the two treatments. Oxidative stress markers told a consistent story: lower malondialdehyde (MDA), higher total antioxidative capacity (T-AOC), and higher superoxide dismutase (SOD) in both treatment groups. At the molecular level, CS repressed Caspase-3 and Bax activation while increasing Bcl-2, and acted on MAPK signaling in a specific direction: decreasing JNK protein expression and increasing ERK protein expression.
The finding that CS performed comparably to an established pharmaceutical antioxidant in this model is notable, though the doses and routes of administration may not translate directly to human clinical practice.
Converging Mechanisms: What the Evidence Map Shows
A 2022 review by Tan et al. synthesized the cordyceps-renal fibrosis literature across disease models (not limited to diabetes), focusing on the effects of Cordyceps on inflammation, oxidative stress, apoptosis, regulation of autophagy, reduction of extracellular matrix deposition, and fibroblast activation.[8]
The DKD-specific studies covered in this article map cleanly onto this framework:
| Mechanism | Study | Key Finding |
|---|---|---|
| Anti-fibrotic (EMT inhibition) | Dong et al. 2019 | CS-N suppressed p38/ERK, blocked EMT |
| Autophagy induction | Cao et al. 2019 | Cordycepin rescued Beclin1/LC3, 3-MA abolished effect |
| Podocyte protection | Hao et al. 2014 | Nephrin/podocin restored, urinary protein reduced |
| Anti-apoptotic (tubular cells) | Zhang et al. 2023 | Caspase-3/Bax down, P-AKT/P-ERK down, PTEN up |
| Anti-oxidant | Zhao et al. 2018 | MDA down, SOD/T-AOC up, comparable to probucol |
| miRNA-mediated | Zheng et al. 2023 | miR-193b-5p/MCL-1 axis identified |
These mechanisms are not independent. Oxidative stress drives apoptosis, which drives fibrosis, which impairs autophagy. Cordyceps compounds appear to intervene at multiple points in this cascade, which is consistent with a multi-component natural product but makes isolating the primary therapeutic target difficult. The Liu et al. (2022) review names this problem directly, calling the poly-component, multi-target character of traditional Chinese medicine "a double-edged sword": although several main active ingredients have been identified — cordycepin, adenosine, and various polysaccharides among them — many constituents still have unclear effects and functions, and the review flags optimal therapeutic dose as an open question that remains to be settled.[1]
What the Human Trials Actually Found
The mechanistic studies above are all preclinical, but the human literature is not empty — it is large, and it is weak, and those two facts have to be held together.
Tan et al. (2022) identified four separate meta-analyses of Cordyceps preparations (Jinshuibao capsule and Bailing capsule) in diabetic nephropathy. Between them they pooled 51 randomized trials with 3,955 participants, 26 trials with 2,198 early-DN participants, 60 studies with 4,288 participants, and 24 studies with 1,941 participants.[8] All four reached the same conclusion: a Cordyceps preparation combined with an ACE inhibitor or ARB was superior to the ACE inhibitor or ARB alone, with a higher overall response rate and lower 24-hour urinary total protein, urinary albumin excretion rate, blood urea nitrogen, and serum creatinine. None of the four showed serious publication bias.
Liu et al. (2022) report the same pattern and extend it: clinical studies found that Bailing capsule combined with ACEI/ARB or with SGLT2 inhibitors significantly reduced urinary protein excretion, alleviated kidney damage, and delayed DKD progression compared with those drugs used alone.[1]
That sounds like a substantial clinical evidence base, and by participant count it is. The problem is what the reviewers say next.
Sample Size vs Evidence Quality
The Rigorous Studies Are the Small Ones
Supplement evidence usually fails in a predictable direction: good mechanism, no humans. Here the human trials exist and are large. What they lack is rigor — and the reviewers who pooled them say so in the same paper that reports the benefit.
Preclinical
High rigorRodents and cell lines. Sample sizes in the dozens.
CS-N purified by microporous resin and glucan columns, constituents identified by HPLC-DAD and LC-MS — not an undefined whole-fungus powder
Dong 2019
Three doses (10, 100, 500 mg/kg) with dose-dependent response, and 3-MA blockade abolishing the anti-fibrotic effect in vitro
Cao 2019
MCL-1 confirmed as a direct target of miR-193b-5p by luciferase reporter assay, not inferred from expression alone
Zheng 2023
Nine targets predicted by network pharmacology and molecular docking, then verified experimentally by qRT-PCR and western blot
Zhang 2023
What it cannot tell you: whether any of this happens in a human kidney.
Clinical
Low rigorFour meta-analyses of Bailing and Jinshuibao capsules, all favouring Cordyceps as add-on therapy.
Shown separately, not summed — these reviews draw on overlapping trials, so a combined total would double-count patients.
What the reviewers said next
- All participants Chinese, no other ethnicity represented
- Most included RCTs did not report detailed methodologies
- Efficacy assessments were not standardised or rigorous
- Low study-design quality and significant heterogeneity
Their verdict: these limitations “reduced the credibility of the meta-analysis.”
Why this matters
Pooling cannot create rigor that the underlying trials never had. Combining two dozen unblinded, poorly-reported studies narrows the confidence interval around an estimate that may be biased — it does not make the estimate more trustworthy. So the large numbers on the right are not the strong evidence and the small numbers on the left are not the weak evidence. The honest summary is that cordyceps has a well-characterised mechanism in rodents and an unresolved effect in humans, and the missing study is a single properly-reported trial, not another meta-analysis of the same material.
Source: Tan et al., 2022; Dong 2019; Cao 2019; Zheng 2023; Zhang 2023 (see references)
Tan et al. list the disqualifiers plainly: every participant across all four meta-analyses was Chinese, with no other ethnicity represented; most of the included randomized trials did not report detailed methodology; efficacy assessments were neither standardized nor rigorous; and the low quality of study design combined with significant heterogeneity "reduced the credibility of the meta-analysis."[8] Tan's own bottom line is that randomized controlled trials with good methodological quality, favorable experimental design, and large sample size are still needed to evaluate the efficacy and safety of Cordyceps.
- Cell studiescompleted
HK-2 human proximal tubular cells under 30 mM glucose, across multiple independent groups, with pathway-level and miRNA-level mechanisms identified
- Animal studiescompleted
Streptozotocin-induced diabetic rats and mice, including a dose-response design and an autophagy-blockade causal test
- Small human trialscompleted
Dozens of randomized trials of Bailing and Jinshuibao capsules as add-on therapy, but most without detailed reported methodology and all in Chinese populations
- Large, rigorous RCTmissing
No adequately powered, well-reported trial with standardized efficacy assessment, and none measuring progression to end-stage renal failure
- Meta-analysiscurrent
Four meta-analyses covering 51, 26, 60 and 24 studies all favour Cordyceps as add-on therapy — but their authors state that low design quality and heterogeneity reduce their credibility
This is an unusual evidence profile: the ladder is climbed to the top and the top rung is unstable. Meta-analyses exist and agree, yet the trials feeding them are the weakest link, and the rung that would normally support them — a large, rigorously reported RCT — was skipped. The preclinical base is genuinely strong; the clinical base is wide but shallow.
Tan et al., 2022 [8]; Liu et al., 2022 [1]
What the Evidence Does Not Show
Every primary study covered in this article is preclinical. Streptozotocin-induced diabetic rats and high-glucose cell cultures are standard models, but they do not replicate the full complexity of human DKD, which develops over years alongside hypertension, dyslipidemia, and genetic susceptibility factors.
No published trial has evaluated whether cordyceps or its derivatives prevent progression from early DKD to end-stage renal failure — the outcome that actually defines the disease. Every clinical result described above is a biomarker result: proteinuria, albumin excretion, creatinine, urea nitrogen. Those markers track with progression, but improving a marker is not the same as preventing a kidney from failing, and the trials were not designed or followed long enough to answer that question.
The comparisons are also structured in a specific way that is easy to over-read. The human trials are add-on designs — Cordyceps plus an ACE inhibitor, ARB, or SGLT2 inhibitor versus that drug alone. That answers whether Cordyceps adds something to standard care in these cohorts. It does not establish that cordyceps preparations are comparable to standard-of-care kidney-protective drugs, because no trial has tested them head-to-head; and it says nothing at all about cordyceps used instead of those drugs, which no trial has tested and which no reviewer in this literature proposes.
Finally, almost none of this transfers cleanly to consumer supplements. The clinical data concerns specific pharmaceutical-grade fermented preparations approved for medical use in China; the preclinical data concerns chemically characterized extracts, isolated cordycepin at defined milligram-per-kilogram doses, and in one case a fraction purified by resin and glucan columns. The preclinical mechanisms are plausible and converging, but the clinical translation gap remains wide.
Clinical Context
CriticalDiabetic kidney disease is not a self-treatment condition
Concern
The entire human evidence base for cordyceps in diabetic kidney disease consists of add-on trials, in which an approved fermented preparation was given alongside an ACE inhibitor, ARB, or SGLT2 inhibitor under medical supervision. Nothing in this literature supports substituting a cordyceps supplement for those drugs, and no trial has tested cordyceps as a standalone therapy for DKD. Untreated or under-treated diabetic kidney disease progresses to dialysis or transplant.
What the research says
Cordyceps preparations were studied as an adjunct to conventional therapy, never as a replacement for it, and the reviewers of this literature consistently frame them that way. The preparations tested were regulated products used in hospital settings — Bailing, Zhiling and Jinshuibao capsules — not over-the-counter supplements, whose cordycepin and nucleoside content is not equivalent and generally not verified.
Particularly relevant for: Anyone with diagnosed diabetic kidney disease, reduced eGFR, or persistent proteinuria, and anyone taking ACE inhibitors, ARBs, SGLT2 inhibitors, or immunosuppressants
What to do
Treat any cordyceps use as a decision to make with the clinician managing your kidney function, not instead of them, and do not alter prescribed medication on the basis of preclinical findings. This article is research summary, not medical advice.
Liu et al., 2022 [1]; Tan et al., 2022 [8]
For a broader comparison of mushroom species studied for diabetic complications, see Comparing mushroom species for diabetes management: which has the strongest evidence?.
The Bottom Line
Cordyceps sinensis and its active compound cordycepin target multiple pathways involved in diabetic kidney disease: protecting tubular cells from apoptosis, inhibiting the epithelial-mesenchymal transition that drives fibrosis, rescuing impaired autophagy, restoring podocyte barrier proteins, and reducing oxidative stress. Six preclinical studies map these mechanisms with increasing molecular specificity, from whole-extract effects to a defined microRNA target, and two reviews place them in context. Human data is not absent — four meta-analyses, the largest pooling 60 studies and 4,288 participants, agree that Cordyceps preparations added to an ACE inhibitor or ARB outperform those drugs alone — but the reviewers who compiled them state that low study-design quality, undisclosed methodology, non-standardized efficacy assessment, and a uniformly Chinese participant population reduce their credibility. The gap is therefore not an absence of clinical research but an absence of rigorous clinical research, and no trial has yet tested whether cordyceps changes progression to end-stage renal failure rather than biomarkers alone.
Frequently Asked Questions
Sources & References
- 1RTHM-00783·Liu, Wu et al. (2022). “Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review..” Frontiers in pharmacology.Study breakdown →PubMed →↩
- 2RTHM-00861·Zhang, Yuhan et al. (2023). “Protective effect of Cordyceps sinensis against diabetic kidney disease through promoting proliferation and inhibiting apoptosis of renal proximal tubular cells..” BMC complementary medicine and therapies.Study breakdown →PubMed →↩
- 3RTHM-00552·Dong, Zhonghua et al. (2019). “A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial-Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy..” Molecules (Basel.Study breakdown →PubMed →↩
- 4RTHM-00547·Cao, Tao et al. (2019). “The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro..” International urology and nephrology.Study breakdown →PubMed →↩
- 5RTHM-00862·Zheng, Rong et al. (2023). “Cordycepin from Cordyceps militaris ameliorates diabetic nephropathy via the miR-193b-5p/MCL-1 axis..” Chinese medicine.Study breakdown →PubMed →↩
- 6RTHM-00325·Hao, Li et al. (2014). “Effect of Cordyceps sinensis and Tripterygium wilfordii polyglycosidium on podocytes in rats with diabetic nephropathy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩
- 7RTHM-00539·Zhao, Kai et al. (2018). “Cordyceps sinensis prevents contrast-induced nephropathy in diabetic rats: its underlying mechanism..” International journal of clinical and experimental pathology.Study breakdown →PubMed →↩
- 8RTHM-00798·Tan, Wei et al. (2022). “Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products..” Frontiers in pharmacology.Study breakdown →PubMed →↩